

Hindustan Unilever

India | FMCG | Company Update



12 February 2026

Focus remains on volume growth

Hindustan Unilever (HUVR IN) posted revenue growth at 6% YoY and 4% underlying volume growth (UVG) in Q3FY26. Growth was broad-based and competitive amid signs of demand recovery, led by easing food inflation, improved consumer sentiments, GST stabilization and policy tailwinds. Management has made strategic changes to make it more agile as it aims to focus on volume growth. We reiterate **Accumulate** with a lower TP of INR 2,635 on 50x FY28E P/E to factor in slow growth and challenges to reach double-digit EPS growth.

Improved Q3 growth with GST transition behind us: HUVR reported a 5.3% YoY increase in consolidated revenue to INR 16.4bn in Q3 with UVG of 4%, the highest recorded in the past 12 quarters. The home care segment remains a drag with 3% revenue growth while rest of the segments reported 6% revenue growth. Double-digit growth was witnessed in the Winter portfolio, and hair, premium skin & oral care. Growth was supported by premiumization, successful new launches, and channel initiatives especially in quick commerce. Minimalist posted strong double-digit performance during the quarter. Management expects H2FY26 to be better than H1 and FY27 growth to be stronger than FY26, aided by improving macros and internal strategic actions.

Strategic reset under new leadership: focus on volume-led growth: HUVR is focused on competitive, volume-led revenue growth through a four-pillar strategy centred on radical consumer segmentation, modernizing core brands, future-proofing marketing & sales, and doubling down on high-growth spaces. On the sales front, it has set up a dedicated qCommerce organization with category partnerships (*Blinkit, Instamart, Zepto*) and significantly improved supply chain capabilities. The company is scaling masstige & D2C (Minimalist & OZiva ~INR 11bn average run rate (ARR), bodywash (~3x turnover in the past three years), new *TRESemmé Hydra Matrix* range to better appeal to the youth and laundry premiumization through the new INR 99 *Surf Excel Easy Wash* accessible pack. Organizational changes under the "Unified India" strategy (direct business unit reporting to CEO, dedicated CMO, single India R&D) aim to bolster agility and India-centric innovation. The company has approved the acquisition of the remaining 49% in OZiva and divestment of 19.8% stake in Nutritionalab.

Retains EBITDA margin guidance: EBITDA margin stood at 22.7%, lower than our estimates due to higher-than-estimated employee expenses (+21.9%, one-off at INR 1.13bn). Adjusted for employee cost, EBITDA margin at 23.4% was 30bp better than our estimates. Gross margin improved +5bp YoY to 51.2%. Management remains committed to investing in growth and retains near-term EBITDA margin guidance of ~22-23%, and additional ~50-60bp benefits from the ice-cream demerger.

Reiterate Accumulate with a lower TP of INR 2,635: We cut our EPS by 0.4% for FY26E, 3.5% for FY27E and 2.9% for FY28E to factor in lower revenue and profitability. We reiterate **Accumulate** with a lower TP of INR 2,635 from INR 2,780 on 50x (from 55x) FY28E P/E as we roll forward.

Key financials

YE March (INR mn)	FY24	FY25	FY26E	FY27E	FY28E
Revenue (INR mn)	618,960	631,210	653,400	699,138	748,078
YoY (%)	2.2	2.0	3.5	7.0	7.0
EBITDA (INR mn)	146,630	148,510	151,131	164,276	178,696
EBITDA margin (%)	23.7	23.5	23.1	23.5	23.9
Adj PAT (INR mn)	102,710	103,440	105,558	113,602	123,858
YoY (%)	0.9	0.7	2.0	7.6	9.0
Fully DEPS (INR)	43.7	44.0	44.9	48.3	52.7
RoE (%)	20.2	20.5	21.2	22.6	24.4
RoCE (%)	25.7	25.9	26.7	28.9	31.3
P/E (x)	55.1	54.7	53.6	49.8	45.7
EV/EBITDA (x)	38.2	37.7	37.1	34.1	31.3

Note: Pricing as on 12 February 2026; Source: Company, Elara Securities Estimate

Rating: [Accumulate](#)
 Target Price: [INR 2,635](#)
 Upside: [9%](#)
 CMP: [INR 2,410](#)
 As on 12 February 2026

Key data

Bloomberg	HUVR IN
Reuters Code	HLLNS
Shares outstanding (mn)	2,350
Market cap (INR bn/USD mn)	5,662/62,494
EV (INR bn/USD mn)	5,602/61,829
ADTV 3M (INR mn/USD mn)	3,799/42
52 week high/low	2,737/2,103
Free float (%)	38

Note: as on 12 February 2026; Source: Bloomberg

Price chart



Source: Bloomberg

	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26
Shareholding (%)				
Promoter	61.9	61.9	61.9	61.9
% Pledge	0.0	0.0	0.0	0.0
FII	10.5	10.2	10.8	10.7
DII	15.6	16.1	15.7	15.8
Others	12.0	11.9	11.6	11.6

Source: BSE

Price performance (%)	3M	6M	12M
Nifty	(0.3)	5.4	12.0
Hindustan Unilever	1.0	(1.5)	4.9
NSE Mid-cap	(0.4)	5.9	15.5
NSE Small-cap	(5.1)	(2.2)	8.0

Source: Bloomberg

Amit Purohit

Building Materials, FMCG, Paints

+91 22 6164 8594
 amit.purohit@elaracapital.com

Associate
 Manas Rastogi
 manas.rastogi@elaracapital.com

Shweta Upadhyay
 shweta.upadhyay@elaracapital.com



Financials (YE March)

Income Statement (INR mn)	FY24	FY25	FY26E	FY27E	FY28E
Total Revenue	618,960	631,210	653,400	699,138	748,078
Gross Profit	321,360	325,430	336,870	362,549	390,171
EBITDA	146,630	148,510	151,131	164,276	178,696
EBIT	134,470	134,960	137,331	150,276	163,796
Interest expense	3,340	3,950	4,270	4,200	4,200
Other income	8,110	10,170	6,751	7,026	7,329
Exceptional/ Extra-ordinary items	60	3,050	570	-	-
PBT	139,300	144,230	140,382	153,102	166,925
Tax	36,440	37,440	34,254	39,500	43,067
Minority interest/Associates income	(90)	(300)	-	-	-
Reported PAT	102,770	106,490	106,128	113,602	123,858
Adjusted PAT	102,710	103,440	105,558	113,602	123,858
Balance Sheet (INR mn)	FY24	FY25	FY26E	FY27E	FY28E
Shareholders' Equity	512,180	494,020	498,711	503,146	507,982
Minority Interest	2,050	2,070	2,070	2,070	2,070
Trade Payables	171,190	197,350	205,351	218,676	232,789
Provisions & Other Current Liabilities	19,160	22,030	21,430	22,821	24,293
Total Borrowings	14,840	16,480	16,480	16,480	16,480
Other long term liabilities	65,470	66,680	66,680	66,680	66,680
Total liabilities & equity	784,890	798,630	810,722	829,873	850,295
Net Fixed Assets	373,030	378,780	369,980	360,980	351,080
Goodwill	174,660	174,660	174,660	174,660	174,660
Intangible assets	-	-	-	-	-
Business Investments / other NC assets	670	590	590	590	590
Cash, Bank Balances & treasury investments	121,170	113,050	127,096	143,980	162,088
Inventories	40,220	44,150	45,236	48,402	51,790
Sundry Debtors	29,970	38,190	39,129	41,868	44,799
Other Current Assets	45,170	49,210	54,031	59,393	65,288
Total Assets	784,890	798,630	810,722	829,873	850,295
Cash Flow Statement (INR mn)	FY24	FY25	FY26E	FY27E	FY28E
Cashflow from Operations	157,920	133,480	120,484	131,050	142,130
Capital expenditure	(21,750)	(19,300)	(5,000)	(5,000)	(5,000)
Acquisitions / divestitures	-	-	-	-	-
Other Business cashflow	-	-	-	-	-
Free Cash Flow	136,170	114,180	115,484	126,050	137,130
Cashflow from Financing	(89,890)	(122,300)	(101,437)	(109,166)	(119,022)
Net Change in Cash / treasury investments	46,280	(8,120)	14,046	16,884	18,107
Key assumptions & Ratios	FY24	FY25	FY26E	FY27E	FY28E
Dividend per share (INR)	42.0	42.3	43.2	46.5	50.6
Book value per share (INR)	217.9	210.2	212.2	214.1	216.2
RoCE (Pre-tax) (%)	25.7	25.9	26.7	28.9	31.3
ROIC (Pre-tax) (%)	31.6	33.4	34.8	39.1	44.1
ROE (%)	20.2	20.5	21.2	22.6	24.4
Asset Turnover (x)	1.7	1.7	1.7	1.9	2.1
Net Debt to Equity (x)	(0.2)	(0.2)	(0.2)	(0.3)	(0.3)
Net Debt to EBITDA (x)	(0.7)	(0.7)	(0.7)	(0.8)	(0.8)
Interest cover (x) (EBITDA/ int exp)	43.9	37.6	35.4	39.1	42.5
Total Working capital days (WC/rev)	27.5	14.7	22.0	28.1	33.7
Valuation	FY24	FY25	FY26E	FY27E	FY28E
P/E (x)	55.1	54.7	53.6	49.8	45.7
P/Sales (x)	9.1	9.0	8.7	8.1	7.6
EV/ EBITDA (x)	38.2	37.7	37.1	34.1	31.3
EV/ OCF (x)	35.5	42.0	46.5	42.7	39.4
FCF Yield	2.4	2.0	2.1	2.3	2.4
Price to BV (x)	11.1	11.5	11.4	11.3	11.1
Dividend yield (%)	1.7	1.8	1.8	1.9	2.1

Note: Pricing as on 12 February 2026; Source: Company, Elara Securities Estimate

We expect a revenue CAGR of 5.8% during FY25-28E

Exhibit 1: Quarterly financials


YE March (INR mn)	Q3FY26	Q3FY25	YoY (%)	Q2FY26	QoQ (%)	Q3FY26E	Variance (%)
Net Sales	163,740	155,560	5.3	165,140	(0.8)	164,436	(0.4)
Operating Expenses	126,530	118,670	6.6	127,960	(1.1)	126,423	0.1
% of Sales	77.3	76.3		77.5		76.9	
EBITDA	37,210	36,890	0.9	37,180	0.1	38,013	(2.1)
EBITDA Margin (%)	22.7	23.7		22.5		23.1	
Other Income	1,390	2,320	(40.1)	2,010	(30.8)	2,300	(39.6)
Interest	880	1,090		1,270		1,250	
Depreciation	3,370	3,180		3,610	(6.6)	3,600	(6.4)
PBT	34,350	34,940	(1.7)	34,310	0.1	35,463	(3.1)
Tax	8,010	10,060	(20.4)	5,350	49.7	9,066	(11.6)
Effective Tax Rate (%)	23.3	28.8		15.6		25.6	
Reported PAT	66,060	29,880	121.1	27,690	138.6	26,268	151.5
Adjusted PAT	26,340	24,880	5.9	28,960	(9.0)	26,398	(0.2)
NPM (%)	16.1	16.0		17.5		16.1	

Source: Company, Elara Securities Estimate

Exhibit 2: Key ratios


YE March (%)	Q3FY26	Q3FY25	YoY bp chg	Q2FY26	QoQ bp chg	Q3FY26E	bp variance
Raw Material Cost	48.8	48.9	(5)	49.9	(110)	48.3	50
Staff Costs	5.6	4.6	101	4.4	119	4.6	102
Advertising Expenses	9.3	9.6	(26)	10.0	(73)	10.0	(74)
Other Expenses	13.6	13.3	29	13.2	44	14.0	(39)
Effective Tax rate	23.3	28.8	(547)	15.6	773	25.6	(225)
Gross Margin	51.2	51.1	5	50.1	110	51.7	(50)
EBITDA Margin	22.7	23.7	(99)	22.5	21	23.1	(39)
NPM	40.3	19.2	2,114	16.8	2,358	-	4,034

Source: Company, Elara Securities Research

Exhibit 3: Volume growth recovers post GST stabilization


Source: Company, Elara Securities Research

Exhibit 4: Margin remains stable for the quarter



Source: Company, Elara Securities Research

Exhibit 5: Segment-wise highlights for Q3 – EBIT margin declines YoY across segments

Segment-wise Q3FY26	USG YoY (%)	EBIT margin (%)	EBIT margin YoY change (bp)	Comment
Home care (fabric wash, household care)	3	18.7	(20)	<p>~Home care achieved its highest-ever quarterly market share, further strengthening the company's leadership position.</p> <p>~Fabric wash: Delivered competitive performance with mid-single-digit UVG, supported by strong momentum in the liquids portfolio, which recorded double-digit growth.</p> <p>~Household care: Recorded double-digit UVG, primarily driven by strong dishwash performance, while the liquids portfolio continued to sustain double-digit growth trajectory.</p>
Beauty & wellbeing (hair care, skin care, and colour cosmetics)	6	26.1	(250)	<p>~UVG stood in the low-single-digit range.</p> <p>~Hair care: The segment recorded strong double-digit, volume-led growth across all channels, further strengthening its leadership position in the category.</p> <p>~Skin care and colour cosmetics: The Winter portfolio delivered robust double-digit seasonal growth. However, this was partly offset by weaker performance in the non-Winter portfolio. "Channels of the Future" continues to post strong, competitive double-digit growth.</p> <p>~Health & wellbeing: Oziva sustained strong momentum with double-digit growth, supported by investments in trend-aligned innovation and effective social-first demand generation strategies, driving consistent performance.</p>
Personal care (oral care, skin cleansing)	6	17.8	(10)	<p>~UVG declined in the low-single-digit range</p> <p>~Skin cleansing: The segment delivered mid-single-digit growth, primarily price-led. Premiumization remained a key growth driver, with premium skin cleansing bars registering strong double-digit growth. Bodywash continued to gain traction, further strengthening its leadership position.</p> <p>~Oral care: The category recorded strong double-digit growth, driven by <i>Closeup</i>, with growth supported by both price and volume expansion. The recently launched <i>Closeup White Now</i> has shown encouraging early performance.</p> <p>~Deodorants: The segment delivered double-digit growth on a small base. <i>Rexona</i> strengthened brand visibility through its association as the first global women-only partner for ICC Women's Cricket, reinforcing its positioning around female empowerment.</p>
Foods (packaged food, tea, coffee & ice cream)	6	21	(120)	<p>~UVG was in the high-single-digit range, indicating segment growth was driven by strong consumption demand and volume expansion.</p> <p>~Beverages: Tea delivered mid-single-digit volume growth, while overall revenue grew in the low-single-digit range due to price reductions in a deflationary commodity environment. Coffee continues its strong momentum, registering robust double-digit growth supported by both price and volume expansion.</p> <p>~Lifestyle nutrition: The segment reported high-single-digit growth driven by strong volume expansion on soft base. Recorded double-digit growth, with early signs of recovery, led by consumption-focused initiatives.</p> <p>~Packaged foods: The category delivered high-single-digit growth, supported by strong performance in ketchup, mayonnaise, soups, and Unilever Food Solutions. The company expanded its portfolio by entering the chutneys category under the <i>Kissan</i> master brand.</p>

Source: Company, Elara Securities Research

Exhibit 6: HUVR trades below its five-year average P/E of 55x


Source: Bloomberg, Company, Elara Securities Research

Exhibit 7: Valuation

(INR)	
EPS - FY27E	48.3
EPS - FY28E	52.7
Target multiple (x)	50.0
EPS – FY28E	52.7
Target price	2,635


Source: Elara Securities Estimate

Exhibit 8: Change in estimates

(INR mn)	Old			New			(% change)		
	FY26	FY27	FY28	FY26	FY27	FY28	FY26	FY27	FY28
Revenue	662,743	709,135	758,774	653,400	699,138	748,078	(1.4)	(1.4)	(1.4)
EBITDA	153,145	168,578	181,803	151,131	164,276	178,696	(1.3)	(2.6)	(1.7)
EBITDA (%)	23.1	23.8	24.0	23.1	23.5	23.9	3.0	(30)	(11)
PAT	105,936	117,796	127,648	105,558	113,602	123,858	(0.4)	(3.6)	(3.0)
EPS (INR)	45.1	50.1	54.3	44.9	48.3	52.7	(0.4)	(3.5)	(2.9)
Target price (INR)	2,780			2,635			(5.2)		

Source: Elara Securities Estimate

Coverage History



Date	Rating	Target Price (INR)	Closing Price (INR)
27-Apr-2023	Accumulate	2,900	2,469
20-Jul-2023	Accumulate	2,820	2,703
19-Jan-2024	Reduce	2,600	2,565
24-Apr-2024	Reduce	2,320	2,260
24-Jul-2024	Reduce	2,780	2,766
23-Oct-2024	Accumulate	2,860	2,659
29-Nov-2024	Accumulate	2,720	2,496
22-Jan-2025	Reduce	2,300	2,343
24-Apr-2025	Reduce	2,236	2,325
31-Jul-2025	Accumulate	2,780	2,521
12-Feb-2026	Accumulate	2,635	2,410

Guide to Research Rating

BUY (B)	Absolute Return >+20%
ACCUMULATE (A)	Absolute Return +5% to +20%
REDUCE (R)	Absolute Return -5% to +5%
SELL (S)	Absolute Return < -5%

Disclosures & Confidentiality for non U.S. Investors

The Note is based on our estimates and is being provided to you (herein referred to as the "Recipient") only for information purposes. The sole purpose of this Note is to provide preliminary information on the business activities of the company and the projected financial statements in order to assist the recipient in understanding / evaluating the Proposal. Nothing in this document should be construed as an advice to buy or sell or solicitation to buy or sell the securities of companies referred to in this document. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved) and should consult its own advisors to determine the merits and risks of such an investment. Nevertheless, Elara Securities (India) Private Limited or any of its affiliates is committed to provide independent and transparent recommendation to its client and would be happy to provide any information in response to specific client queries. Elara Securities (India) Private Limited or any of its affiliates have not independently verified all the information given in this Note and expressly disclaim all liability for any errors and/or omissions, representations or warranties, expressed or implied as contained in this Note. The user assumes the entire risk of any use made of this information. Elara Securities (India) Private Limited or any of its affiliates, their directors and the employees may from time to time, effect or have effected an own account transaction in or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for or solicit investment banking or other business from any company referred to in this Note. Each of these entities functions as a separate, distinct and independent of each other. This Note is strictly confidential and is being furnished to you solely for your information. This Note should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This Note is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Elara Securities (India) Private Limited or any of its affiliates to any registration or licensing requirements within such jurisdiction. The distribution of this document in certain jurisdictions may be restricted by law, and persons in whose possession this document comes, should inform themselves about and observe, any such restrictions. Upon request, the Recipient will promptly return all material received from the company and/or the Advisors without retaining any copies thereof. The Information given in this document is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This Information is subject to change without any prior notice. Elara Securities (India) Private Limited or any of its affiliates reserves the right to make modifications and alterations to this statement as may be required from time to time. However, Elara Securities (India) Private Limited is under no obligation to update or keep the information current. Neither Elara Securities (India) Private Limited nor any of its affiliates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. This Note should not be deemed an indication of the state of affairs of the company nor shall it constitute an indication that there has been no change in the business or state of affairs of the company since the date of publication of this Note. The disclosures of interest statements incorporated in this document are provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. Elara Securities (India) Private Limited generally prohibits its analysts, persons reporting to analysts and their family members from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Any clarifications / queries on the proposal as well as any future communication regarding the proposal should be addressed to Elara Securities (India) Private Limited. It is important to note that any dispute with respect to this research report, would not have access to stock exchange investor redressal forum or arbitration mechanism.

Elara Securities (India) Private Limited was incorporated in July 2007 as a subsidiary of Elara Capital (India) Private Limited.

Elara Securities (India) Private Limited is a SEBI registered Stock Broker in the Capital Market and Futures & Options Segments of National Stock Exchange of India Limited [NSE] and BSE Limited [BSE] and a Depository Participant registered with Central Depository Services (India) Limited [CDSL].

Elara Securities (India) Private Limited's business, amongst other things, is to undertake all associated activities relating to its broking business.

The activities of Elara Securities (India) Private Limited were neither suspended nor has it defaulted with any stock exchange authority with whom it is registered in last five years. However, during the routine course of inspection and based on observations, the exchanges have issued advise letters or levied minor penalties on Elara Securities (India) Private Limited for minor operational deviations in certain cases. Elara Securities (India) Private Limited has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has the certificate of registration been cancelled by SEBI at any point of time.

Elara Securities (India) Private Limited offers research services primarily to institutional investors and their employees, directors, fund managers, advisors who are registered or proposed to be registered.

Details of Associates of Elara Securities (India) Private Limited are available on group company website www.elaracapital.com

Elara Securities (India) Private Limited is maintaining arms-length relationship with its associate entities.

Research Analyst or his/her relative(s) may have financial interest in the subject company. Elara Securities (India) Private Limited does not have any financial interest in the subject company, whereas its associate entities may have financial interest. Research Analyst or his/her relative does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Elara Securities (India) Private Limited does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Associate entities of Elara Securities (India) Private Limited may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Research Analyst or his/her relative or Elara Securities (India) Private Limited or its associate entities does not have any other material conflict of interest at the time of publication of the Research Report.

Artificial Intelligence (AI) tools may have been used only for compilation or collating publicly available research data or internally generated research data during the information gathering and/or summarizing the final report.

Research Analyst or his/her relative(s) has not served as an officer, director or employee of the subject company.

Research analyst or Elara Securities (India) Private Limited have not received any compensation from the subject company in the past twelve months. Associate entities of Elara Securities (India) Private Limited may have received compensation from the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associate entities have not managed or co-managed public offering of securities for the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associate entities may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company or third party in connection with the Research Report in the past twelve months.

Disclaimer & Standard warning

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Disclaimer for non U.S. Investors

The information contained in this note is of a general nature and is not intended to address the circumstances of any particular individual or entity. Although we endeavor to provide accurate and timely information, there can be no guarantee that such information is accurate as of the date it is received or that it will continue to be accurate in the future. No one should act on such information without appropriate professional advice after a thorough examination of the particular situation.

Disclosures for U.S. Investors

Rule 15a6 Disclosure: This research report ("Report") was prepared, approved, published, and distributed by Elara Securities (India) Private Limited a company located outside of the United States (the "Foreign Counterparty"). Avior Capital Markets US LLC ("Avior US"), a US registered broker-dealer, distributes this Report in the US on behalf of the Foreign Counterparty. Only major U.S. institutional investors (as defined in Rule 15a-6 under the US Securities Exchange Act of 1934 (the "Exchange Act")) may receive this Report under the exemption in Rule 15a-6. A US institutional investor must effect any transaction in the securities described in this Report through Avior US.

Neither the Report nor any analyst who prepared or approved the Report is subject to US legal requirements or the Financial Industry Regulatory Authority, Inc. ("FINRA") or other US regulatory requirements concerning research reports or research analysts. The Foreign Counterparty is not a registered broker-dealer under the Exchange Act nor is it a member of the Financial Industry Regulatory Authority, Inc., or any other US self-regulatory organisation.

Disclosures on Subject Companies: Analysts of the Foreign Counterparty produced this material solely for informational purposes and the use of the intended recipient. No person may reproduce, this Report under any circumstances. No person may copy or make this Report available to any other person other than the intended recipient.

Avior US distributes this Report in the United States of America. The Foreign Counterparty distributes this Report elsewhere in the world. This document is not an offer, or invitation by or on behalf of Avior US, the Foreign Counterparty, their affiliates, or any other person, to buy or sell any security.

Avior US and the Foreign Counterparty and their affiliates obtained the information contained herein from published information and other sources, which Avior US and the Foreign Counterparty and their affiliates reasonably consider to be reliable.

Avior US and the Foreign Counterparty accept no liability or responsibility whatsoever for the accuracy or completeness of any such information. All estimates, expressions of opinion and other subjective judgments contained herein are valid as of the date of this document. Avior US assumes responsibility for the Report content with regards to research distributed in the US.

Neither Avior US nor the Foreign Counterparty has managed or co-managed a public offering of securities for the subject company in the past 12 months, have not received compensation for investment banking services from the subject company in the past 12 months and do not expect to receive and does not intend to seek compensation for investment banking services from the subject company in the next three months. Avior US and the Foreign Counterparty have not owned any class of equity securities of the subject company. There are no other actual, material conflicts of interest of Avior US and the Foreign Counterparty at the time of the publication of this Report. As of the publication of this Report, Avior US nor the Foreign Counterparty makes a market in the subject securities.

Avior US and its affiliates, to the fullest extent permissible by law, accept no liability of any nature whatsoever for any claims, damages or losses arising from, or in connection with, the contents of this Report or the use, reliance, publication, distribution, dissemination, disclosure, alteration or reproduction of this Report, or any views or recommendations recorded therein.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (i) exchange rates can be volatile and are subject to large fluctuations; (ii) the value of currencies may be affected by numerous market factors, including world and national economic, political and regulatory events, events in equity and debt markets and changes in interest rates; and (iii) currencies may be subject to devaluation or government imposed exchange controls which could affect the value of the currency. Investors in securities such as ADRs, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Subject to the applicable laws, all transactions should be executed through Avior US. Aside from within this Report, important conflict disclosures can also be found at <https://aviorcapital.us/us-regulatory-disclosures/and> Investors are strongly encouraged to review this information before investing.

Additional Disclaimer for UK Investors

Note that Elara Securities (India) Private Limited ("Foreign Counterparty") has concluded a MiFID II research intermediary agreement with Avior Capital Markets International Limited ("Avior UK"), regulated by the Financial Conduct Authority (FRN: 191074), pursuant to which Avior UK distributes the Foreign Counterparty's research in the UK, in return for which the Foreign Counterparty pays Avior UK a percentage of the income received in relation to such research. This research report including any recommendations recorded therein ("Report") have been prepared by the Foreign Counterparty, and not by Avior UK.

The Report: (a) has been objectively prepared from public sources which are believed to be reliable and therefore constitutes independent investment research and is presented as such; and (b) may only be distributed to, and relied on by, qualifying investors, who are permitted to receive same in the UK.

Securities, money market instruments, strategies, financial or investment instruments mentioned in this Report may not be suitable for all investors. The information and opinions provided in this Report do not constitute a personal recommendation/investment advice and take no account of the investor's individual circumstances. Investors should consider this Report as only a single factor in making any investment decisions and, if appropriate, should seek advice from an investment advisor. This Report is not an offer, or invitation by or on behalf of Avior UK, the Foreign Counterparty, their affiliates, or any other person, to buy or sell any security.

Save as disclosed otherwise, the Foreign Counterparty's relationship with Avior UK is not reasonably expected to impair the objective presentation of the recommendations in the Report, including any interests or conflicts of interest concerning any financial instruments or the issuers to which the recommendations, directly or indirectly, relate. The Report is deemed to be first disseminated at the date and time recorded on the relevant distribution platform, data network or email (as applicable), and which information is available on request. A list of the Foreign Counterparty's research reports disseminated in the UK over the past 12 months is also available on request.

Avior UK does not assume any responsibility or liability of any nature whatsoever arising from or in connection with the content, use, reliance or dissemination of the Report or any recommendation in respect thereof and disclaims any such liability.

Certification by Each of the Authors of this Report

The analyst(s) (singular includes plural) ("Analyst") certifies that the views expressed in this Report are an accurate representation of the Analyst's personal opinions on the stock or sector as covered and reported on by the Analyst hereinabove. The Analyst furthermore certifies that no part of the Analyst's compensation was, is, or will be related, directly or indirectly, to the specific recommendations or views as expressed in this document. The Analyst is principally responsible for the preparation of this Report and does not have any material conflict of interest at the time of publication of this Report. The Analyst(s) has not served as an officer, director or employee of the subject company in the last 12-month period ending on the last day of the month immediately preceding the date of publication of the Report.

Analyst Certification: In connection with the companies or securities that; each analyst identified in this Report certifies that: The views expressed on the subject companies and securities in this Report reflect their personal views. No part of his or her compensation was, is or will be directly or indirectly dependent on the specific recommendations or views expressed in this Report.

Note that:

- (i) The Foreign Counterparty is the employer of the research analyst(s) responsible for the content of this Report, and
- (ii) Research analysts preparing this Report are resident outside the United States and are not associated persons of any US regulated broker-dealer. Therefore, the analyst(s) are not subject to supervision by a US broker-dealer and are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with US rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

Avior Capital Markets US, LLC is a FINRA registered broker-dealer (CRD # 172595) formed for that purpose in the State of Delaware with its principal office at 45 Rockefeller Plaza, Suite 2335, New York, New York 10111.

Avior Capital Markets International Limited is regulated by the Financial Conduct Authority (FRN: 191074), with its principal office at 10 South Street, Elgin, Scotland IV30 1LE.

Elara Securities (India) Private Limited is a SEBI-registered Research Analyst (Regn. No.: INH000000933), Stock Broker (Regn. No.: INZ000238236) and Depository Participant (Regn. No.: IN-DP-370-2018). Its registered address is One International Center, Tower 3, 21st Floor, Senapati Bapat Marg, Elphinstone Road (West) Mumbai – 400 013, India

India

Elara Securities (India) Private Limited
One International Center, Tower 3,
21st Floor, Senapati Bapat Marg,
Elphinstone Road (West)
Mumbai – 400 013, India
Tel : +91 22 6164 8500

Europe

Elara Capital Plc.
6th Floor, The Grove,
248A Marylebone Road,
London, NW1 6JZ,
United Kingdom
Tel : +44 20 7486 9733

USA

Elara Securities Inc.
230 Park Avenue, Suite 2415,
New York, NY 10169, USA
Tel: +1 212 430 5870
Fax: +1 212 208 2501

Asia / Pacific

Elara Capital (Asia) Pte.Ltd.
One Marina Boulevard,
Level 20,
Singapore 018989
Tel : +65 6978 4047



Managing Director

Harendra Kumar | harendra.kumar@elaracapital.com | +91 22 6164 8571



Head of Research

Dr Bino Pathiparampil | bino.pathiparampil@elaracapital.com | +91 22 6164 8572

Sales Team



India

Hitesh Danak - hitesh.danak@elaracapital.com - +91 22 6164 8543
Ashok Agarwal - ashok.agarwal@elaracapital.com - +91 22 6164 8558
Himani Sanghavi - himani.sanghavi@elaracapital.com - +91 22 6164 8586



India, APAC & Australia

Sudhanshu Rajpal - sudhanshu.rajpal@elaracapital.com - +91 22 6164 8508
Joshua Saldanha - joshua.saldanha@elaracapital.com - +91 22 6164 8541
Shraddha Shrikhande - shraddha.shrikhande@elaracapital.com - +91 22 6164 8567
Suyash Maheshwari - suyash.maheshwari@elaracapital.com - +91 22 4204 8698



India & UK

Prashin Lalvani - prashin.lalvani@elaracapital.com - +91 22 6164 8544



India & US

Karan Rathod - karan.rathod@elaracapital.com - +91 22 6164 8570



Corporate Access, Conference & Events

Anita Nazareth - anita.nazareth@elaracapital.com - +91 22 6164 8520
Tina D'souza - tina.dsouza@elaracapital.com - +91 22 6164 8595

By clicking this link, you acknowledge and agree to the [Terms and Conditions of Research Services](#).

Access our reports on Bloomberg: Type **RESP ESEC <GO>**

Also available on **Thomson & Reuters**

Elara Securities (India) Private Limited

Registered Office Address: One International Center, Tower 3, 21st Floor, Senapati Bapat Marg, Elphinstone Road (West) Mumbai – 400 013, India Tel : +91 22 6164 8500
CIN: U74992MH2007PTC172297 | SEBI Research Analyst Registration No.: INH000000933
Member of BSE Limited and National Stock Exchange of India Limited | SEBI REGN. NO.: INZ000238236
Member of Central Depository Services (India) Limited | SEBI REGN. NO.: IN-DP-370-2018
Investor Grievance Email ID: investor.grievances@elaracapital.com - Tel. +91 22 6164 8509
Compliance Officer: Mr. Anand Rao - Email ID: anand.rao@elaracapital.com - Tel. +91 22 6164 8509